Tango Therapeutics (TNGX) has been on a remarkable upward trajectory, surging 1,229% over the past year. This biotechnology company, valued at $2.98 billion, is dedicated to discovering and delivering precision cancer medicines.
The stock is currently trading at an all-time high, with strong technical momentum backing it up. Barchart maintains a 100% “Buy” technical opinion on TNGX, highlighting its potential for further growth. However, it’s important to note that the short interest in the stock is exceptionally high at 34.16% of the float, indicating a speculative nature and significant risk associated with investing in TNGX.
Despite the impressive performance of the stock, analysts are projecting a decrease in both revenue and earnings for TNGX. Revenue is expected to decline by 89.32% this year and another 47.64% next year, while earnings are estimated to decrease by 51.60% this year and an additional 16.20% next year.
Wall Street analysts followed by Barchart have given TNGX 10 “Strong Buy” and 2 “Hold” opinions, with price targets ranging between $14 and $27. Value Line rates the stock as “Above Average,” while CFRA’s MarketScope rates it as a “Hold.” Morningstar believes the stock is undervalued by 5%, with a fair value of $20.61.
Despite the positive outlook from some analysts, it’s essential to consider the high level of short interest in TNGX, as well as the projected decrease in revenue and earnings. This stock is highly speculative and volatile, making it crucial to approach with caution and consider your risk tolerance before investing.
